Scholar Rock Holding (SRRK) Earnings Date & Reports

Key Takeaways

• Scholar Rock (SRRK) is expected to report its third-quarter 2026 results in mid-November, just weeks after apitegromab's September 30, 2026, Prescription Drug User Fee Act (PDUFA) decision date.
• The company has not yet recorded product revenue, so the update will center on its net loss, operating expenses, and cash balance rather than top-line sales.
• Analysts expect another sizable quarterly loss, in line with recent quarters when losses per share ranged from roughly $0.76 to $0.90.
• Apitegromab, an investigational muscle-targeted therapy for spinal muscular atrophy (SMA), remains the core driver of the story, alongside commercial launch readiness.
• Investors will watch guidance on cash runway and spending as the company moves toward potential commercialization.
• For more detail on SRRK's Major News, Today's Price Move, Price Targets, and Forecast, explore Tickeron's dedicated pages.
• Explore Trending AI Robots on Tickeron to discover AI-driven trading ideas.

Earnings Context and Why It Matters

Scholar Rock is a late-stage biopharmaceutical company built around a "muscle-targeted" approach to treating rare neuromuscular diseases, led by apitegromab for spinal muscular atrophy (SMA). Because the company is still pre-commercial, its quarterly earnings carry unusual weight: investors are not looking for revenue growth but for signals on regulatory progress, launch readiness, and capital discipline. This report arrives against a high-stakes backdrop, with apitegromab's U.S. review timeline and European filing progressing and the company working toward a potential first commercial launch. The financials themselves—mainly a net loss and operating expenses—matter primarily as a gauge of how much cash the company is spending as it approaches commercialization.

Earnings Expectations

Scholar Rock has not yet generated product revenue, and no top-line sales are expected for the third quarter of 2026. Instead, the report will be judged on the net loss and the trajectory of operating expenses. In the second quarter of 2026, the company posted a net loss of $0.84 per share, in line with the consensus estimate, while the first quarter came in at $0.83 per share versus a roughly $0.80 consensus. Recent quarterly losses have ranged from about $0.76 to $0.90 per share, and analysts anticipate a comparable figure for the third quarter.

Key metrics to watch include research and development (R&D) expense, general and administrative (G&A) expense, and stock-based compensation, which has been a recurring non-cash component of results. The cash position is equally important: Scholar Rock ended the second quarter of 2026 with approximately $492 million in cash, cash equivalents, and marketable securities.

The shares have historically reacted more to regulatory and clinical news than to the financials themselves. In November 2025, for example, the stock surged more than 20% despite a wider-than-expected loss, after management described a "constructive" meeting with the U.S. Food and Drug Administration (FDA) regarding the SMA program.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven moves across the biotechnology sector, it offers a practical way to surface candidates worth a closer look.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report is closely tied to apitegromab's regulatory timeline rather than the bottom line. With the PDUFA decision date having passed in late September, investors are likely to treat any commentary on approval status, manufacturing, and commercial launch as more meaningful than the earnings figure itself. Key risk factors include potential delays tied to third-party fill-finish manufacturing, the pace of European Medicines Agency (EMA) review, and the timing of reimbursement and patient access following any approval. Because the stock has shown a pattern of sharp moves on FDA and pipeline updates, the earnings call's forward-looking commentary may matter more to traders than the reported loss.

Forward Outlook and Key Factors to Monitor

Looking past the third-quarter print, the most important variable remains whether apitegromab clears its regulatory hurdles and reaches a commercial launch. Any update on the U.S. Biologics License Application (BLA) review and the readiness of the company's fill-finish facilities will be closely scrutinized, given that manufacturing compliance issues previously delayed the program.

Cash management is another key theme. Scholar Rock's ability to fund a launch while continuing research and development (R&D) will depend on disciplined spending and, potentially, additional financing. Management has indicated the balance sheet is intended to support operations well into 2027, but full commercialization could require further capital.

Finally, investors should monitor the broader pipeline, including the Phase 2 OPAL study in infants and toddlers with SMA, the Phase 2 FORGE study in facioscapulohumeral muscular dystrophy (FSHD), and SRK-439, a next-generation myostatin inhibitor. Progress in these programs could broaden the company's longer-term opportunity beyond its lead indication and shape how the market values the stock after this earnings event.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations